HaroldN.KeerMDPhD

Genitourinary Oncology, Hematologic Oncology

Chief Medical Officer, Taiho Oncology, Inc.

Dr. Keer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Oncologist leading R& D efforts at Taiho Oncology, Inc. as Chief Medical Officer

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1997
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
Northwestern University The Feinberg School of MedicineClass of 1990

PubMed

62 citations
Fibrinolysis and cancer.
Hau C. Kwaan, Harold N. Keer
Seminars in Thrombosis and Hemostasis. 1990-07-01
23 citations
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
Costantine Albany, Zeeshan Fazal, Ratnakar Singh, Emmanuel Bikorimana, Nabil Adra
Cancer Medicine. 2021-01-01
34 citations
Components of the plasminogen-plasmin system in human tumor cell lines.
Hau C. Kwaan, Harold N. Keer, James A. Radosevich, Jean-Francois Cajot, Robin Ernst
Seminars in Thrombosis and Hemostasis. 1991-07-01

Abstracts/Posters

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Harold N. Keer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Astex Announces That the Phase 3 ASCERTAIN - Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial’s Primary EndpointMay 12th, 2022